{
    "nct_id": "NCT05242471",
    "official_title": "A Phase 2b Randomized, Double-blind, Active-and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease",
    "inclusion_criteria": "* Diagnosis of Crohn's disease (CD) for at least 3 months prior to baseline\n* Confirmed diagnosis of moderate to severe CD as assessed by Crohn'\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 65 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}